Vistagen sees fasedienol signal in severe social anxiety

Exploratory subgroup analyses from two trials showed fasedienol reduced anxiety symptoms in participants with very severe social anxiety disorder.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A sleek black and silver remote control rests on a dark wooden nightstand, lit by natural light, next to a bed with white linens and a light-colored pillow.

Vistagen has presented exploratory data at Psych Congress 2026 in New Orleans suggesting its intranasal candidate fasedienol may offer a benefit in people with very severe social anxiety disorder, defined by a Liebowitz Social Anxiety Scale score of 95 or above.

The poster drew on subpopulation analyses from two separate studies: a post-hoc analysis from the Phase 3 PALISADE-4 trial and a prespecified analysis from a Phase 2a repeat-dose study. In both, participants with very severe social anxiety showed statistically significant improvements on the Subjective Units of Distress Scale during a public speaking challenge when treated with fasedienol against placebo.

What the data show

PALISADE-4 is notable because the trial did not meet its primary endpoint in the overall study population. The statistically significant result reported here applies only to the very severe subgroup identified post-hoc, which carries a higher risk of false positives and limits the conclusions that can be drawn without a prospectively powered confirmatory study.

The Phase 2a repeat-dose findings are more structured. A prespecified analysis in the very severe subgroup found a statistically significant improvement after a single dose of fasedienol, with a numerically greater reduction in anxiety scores after a second dose administered ten minutes later. Both populations in that study also showed significant improvements in anticipatory anxiety measured before the speaking challenge. No serious drug-related safety signals were identified in either analysis, and tolerability appeared consistent with earlier trials.

Chief Medical Officer Angel Angelov said the signals "help inform our ongoing evaluation of fasedienol" and highlighted the potential benefit of repeat dosing as an area of interest for further study.

Market context

Social anxiety disorder is among the most prevalent anxiety conditions globally, yet the treatment landscape for severe and very severe presentations remains limited. Approved pharmacological options include SSRIs, SNRIs and benzodiazepines, each carrying tolerability or dependency concerns that leave a meaningful unmet need, particularly for acute situational use. Fasedienol is designed to act via nose-to-brain neurocircuitry without systemic absorption, which the company positions as a potential tolerability advantage over existing agents.

A number of companies are active in CNS approaches targeting anxiety and stress-related disorders, including programmes exploring rapid-onset mechanisms. The acute situational-use segment, where a patient might dose before a high-anxiety event, has attracted renewed interest as the limitations of chronic SSRI use for episodic presentations become better understood.

Vistagen also has itruvone for major depressive disorder and refisolone for vasomotor symptoms in its intranasal pipeline. For fasedienol, the next key milestone will be whether the company pursues a further prospectively designed trial in the very severe subpopulation, or attempts to use the existing dataset to support a regulatory submission strategy with the FDA.

Sector

Topic

Geography